There was no significant difference between non-survivor and survivor patients in terms of the scales used to calculate the severity of liver disease (PELD and MELD scores), INR, total/conjugated bilirubin, alanine aminotransferase and aspartate aminotransferase value. This evidence concerns the gene GPT and liver disorder.